What is the dosage and administration of dexmethylphenidate (Azstarys)

The usage and dosage of dexmethylphenidate（Azstarys） for the treatment of ADHD（ADHD) fully considers the needs of ADHD patients of different ages, and its dosage adjustment needs to be formulated by clinicians based on the individual conditions of the patient. As an oral preparation, its biggest feature is that it can maintain its efficacy all day long once a day. This convenience greatly improves patient compliance.

1. Pediatric patients aged 6-12 years old

The recommended starting dose is39.2mg/7.8mg, taken orally once a day in the morning, with food or on an empty stomach. After one week of taking the drug, if the patient tolerates it well and the efficacy has not yet reached optimal, the dose can be adjusted to 52.3 mg/10.4 mg once a day. If the patient is dose-sensitive or has tolerance issues, the dose may be appropriately reduced to 26.1 mg/5.2 mg once daily. The maximum recommended dose is 52.3mg/10.4mg.

2. Adolescents and adult patients aged 13-17 years old

The recommended starting dose is also 39.2mg/7.8mg, once daily. If the treatment effect is unsatisfactory and tolerance permits, the doctor can increase the dosage to 52.3 mg/10.4 mg once a day.

Dexmethylphenidate tablets must be swallowed whole and not crushed or chewed to ensure the normal release mechanism of the drug in the body. Because it is a central nervous system stimulant drug, it has a certain risk of abuse and dependence potential, so it must be used strictly in accordance with the doctor's prescription, and regular follow-up is required to monitor side effects and efficacy.

In practical applications, the convenience of dexmethylphenidate has significantly reduced the compliance problems caused by the need for multiple refills in children in the school environment, and also reduced the instability when the drug effect wears off. For adult patients, one dose can cover the entire working day, greatly improving quality of life and work efficiency. With the accumulation of overseas clinical experience, the dosage management of dexmethylphenidate provides an important reference for its future entry into the Chinese market.

Reference materials:https://azstarys.com/